Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
ViiV Healthcare receives EU Marketing Authorisation for the first-ever dispersible-tablet formulation of dolutegravir, Tivicay, a treatment for children living with HIV in Europe
The EU Marketing Authorisation follows the US Food and Drug Administration (FDA) approval of Tivicay PD in 2020.
Read more -
Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
Second monoclonal antibody from Vir-GSK collaboration to be investigated as a potential COVID-19 treatment.
Read more -
GSK, MMV filing for Kozenis (tafenoquine) in paediatric populations with Plasmodium vivax malaria accepted by Australian Therapeutic Goods Administration
The application includes data for a new, 50 mg tablet that can be dispersed in water and which was developed to facilitate use in children.
Read more -
ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe
New treatment can enable people living with HIV to reduce the days they receive treatment from 365 to 12 or 6 per year
Read more -
GSK and Ahren Announce Co-Led Series A Investment in Adrestia, and Multi-Project Discovery Collaboration with Each of the Five Projects Eligible To Receive Up To $230M (£172M) in Post Option Milestones
The multi-year collaboration agreement seeks to discover novel drug targets across a number of therapeutic areas
Read more -
FDA approves GSK’s BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US
Approval builds on nearly 10 years of experience in lupus
Read more -
Vir Biotechnology and GSK announce start of NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19
Global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalised adults with COVID-19
Read more -
ViiV Healthcare announces positive CHMP opinion for Rukobia (fostemsavir), a first-in-class attachment inhibitor for the treatment of adults with multidrug-resistant HIV with few treatment options available
Fostemsavir addresses a critical unmet need in HIV care for those with little to no treatment options left.
Read more -
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine programme to improve immune response in the elderly
Phase 1/2 interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years
Read more -
FDA accepts GSK’s filing of Nucala (mepolizumab) for use in chronic rhinosinusitis with nasal polyps
If approved, Nucala would be the only treatment approved in the US for use in four eosinophil-driven diseases.
Read more -
GSK starts phase 3 study of RSV maternal candidate vaccine
RSV is a leading cause of respiratory infections such as bronchiolitis and viral pneumonia in infants.
Read more -
GSK and MMV present positive data on treatment for Plasmodium vivax malaria in children from 6 months up to 15 years of age
The results of the TEACH study were presented during the American Society of Tropical Medicine & Hygiene 2020 virtual annual meeting.
Read more -
ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention
This is intended to facilitate the development and expedite the review of drugs that address serious or life-threatening medical conditions.
Read more -
GSK presents Phase 2b data on linerixibat for the treatment of cholestatic pruritus in primary biliary cholangitis (PBC)
The Phase 2b GLIMMER study was presented today at The Liver Meeting® 2020.
Read more -
ViiV Healthcare announces CHMP positive opinion for the first-ever dispersible-tablet formulation of dolutegravir, Tivicay, a treatment for children living with HIV in Europe
This CHMP positive opinion paves the way to expand the use of dolutegravir in a younger population.
Read more -
Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate
Based on the positive Phase 1 results, Medicago has decided to launch the Phase 2/3 clinical trial with GSK’s pandemic adjuvant.
Read more -
GSK highlights progress from the BLENREP (belantamab mafodotin-blmf) development programme in multiple myeloma at ASH Annual Meeting
Studies presented will demonstrate belantamab mafodotin's potential in combination with standard therapies in earlier lines of treatment.
Read more -
ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women
The study showed cabotegravir was 89% more effective than daily oral FTC/TDF for pre-exposure prophylaxis (PrEP).
Read more -
GSK sets new environmental goals of net zero impact on climate and net positive impact on nature by 2030
The new goals support GSK's aim to create long-term value for shareholders and meet the needs of society.
Read more -
GSK Nucala (mepolizumab) filings accepted by European Medicines Agency for three additional eosinophil-driven diseases
If approved in the EU, Nucala would be the only treatment indicated for four eosinophil-driven diseases.
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
